###begin article-title 0
Th17 cells enhance viral persistence and inhibit T cell cytotoxicity in a model of chronic virus infection
###end article-title 0
###begin p 1
###xml 453 459 <span type="species:ncbi:10090">murine</span>
Persistent viral infection and its associated chronic diseases are a global health concern. Interleukin (IL) 17-producing Th17 cells have been implicated in the pathogenesis of various autoimmune diseases, and in protection from bacterial or fungal infection. However, the role of Th17 cells in persistent viral infection remains unknown. We report that Th17 cells preferentially develop in vitro and in vivo in an IL-6-dependent manner after Theiler's murine encephalomyelitis virus infection. Th17 cells promote persistent viral infection and induce the pathogenesis of chronic demyelinating disease. IL-17 up-regulates antiapoptotic molecules and, consequently, increases persistent infection by enhancing the survival of virus-infected cells and blocking target cell destruction by cytotoxic T cells. Neutralization of IL-17 augments virus clearance by eliminating virus-infected cells and boosting lytic function by cytotoxic T cells, leading to the prevention of disease development. Thus, these results indicate a novel pathogenic role of Th17 cells via IL-17 in persistent viral infection and its associated chronic inflammatory diseases.
###end p 1
###begin p 2
###xml 549 550 549 550 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib1">1</xref>
###xml 615 616 615 616 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 783 784 783 784 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib2">2</xref>
###xml 785 787 785 787 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib10">10</xref>
###xml 902 904 902 904 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib11">11</xref>
###xml 905 907 905 907 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib13">13</xref>
###xml 984 986 984 986 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib14">14</xref>
###xml 987 989 987 989 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib17">17</xref>
###xml 1018 1020 1018 1020 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib18">18</xref>
###xml 1066 1068 1066 1068 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib19">19</xref>
###xml 959 962 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 976 982 <span type="species:ncbi:9606">humans</span>
###xml 1026 1053 <span type="species:ncbi:12814">respiratory syncytial virus</span>
When an immune response is triggered by microbial pathogens, the innate immune system directs T lymphocytes to achieve appropriate effector function from diverse pathways to protect the host against destructive invasion. However, in some cases, inappropriate T effector cells that are unable to control microbial infections are induced and expanded, thereby allowing pathogens to persist in the host. For example, the balance between Th1 and Th2 responses to an infectious agent may determine the outcome of immunoprotection versus immunopathology (1). IL-17-producing Th17 cells, which are a distinct subset of CD4+ T cells, comprise another T effector cell type that is apparently involved in inflammatory tissue damage, leading to the pathogenesis of various autoimmune diseases (2-10). Furthermore, Th17 also appears to play a role in protection against extracellular bacterial or fungal diseases (11-13). The production of IL-17 has been reported during HIV infection in humans (14-17), and herpes simplex virus (18) and respiratory syncytial virus infections (19) in rodents. However, the induction of Th17 cells during persistent viral infection, and their potential roles in the establishment of viral persistence and the pathogenesis of chronic viral infection-associated diseases remain undefined.
###end p 2
###begin p 3
###xml 32 33 32 33 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 103 104 103 104 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib1">1</xref>
###xml 106 108 106 108 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib20">20</xref>
###xml 225 226 221 222 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib2">2</xref>
###xml 228 229 224 225 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib4">4</xref>
###xml 338 340 334 336 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib21">21</xref>
###xml 475 477 471 473 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib22">22</xref>
###xml 479 481 475 477 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib23">23</xref>
###xml 596 598 592 594 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib24">24</xref>
###xml 692 693 688 689 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 704 705 700 701 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 715 717 711 713 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib25">25</xref>
###xml 1014 1016 1010 1012 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib26">26</xref>
###xml 1033 1035 1029 1031 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib27">27</xref>
###xml 248 277 <span type="species:ncbi:11723">simian immunodeficiency virus</span>
###xml 287 302 <span type="species:ncbi:9544">rhesus macaques</span>
During viral infection, most CD4+ T cells isolated from the virus target organ belong to the Th1 type (1, 20). Th1 cytokines, such as IFN-gamma, display strong antiviral function and antagonize the development of Th17 cells (2, 4). For example, in simian immunodeficiency virus-infected rhesus macaques, Th17 cells are markedly depleted (21). The induction of type I IFNs and their downstream signaling pathways in response to viral infection may constrain Th17 development (22, 23). In opposition to this protective strategy, a virus may be able to evade antiviral types I and II IFN responses (24), facilitating its persistence in the host by inducing elevated levels of IL-17-producing CD4+ and/or CD8+ T cells (25). However, the potential role of Th17 cells in the pathogenesis of virus-induced chronic inflammatory diseases is virtually unknown. Th17 cells, via their cytokine IL-17, play a pivotal role in mediating different types of tissue inflammation and destruction in chronic toxoplasmic encephalitis (26) and psoriasis (27). Therefore, it is conceivable that persistent chronic viral infection might be associated with a polarized Th17 response that may further exert a positive or negative feedback loop on viral persistence and the pathogenesis of virus-induced chronic diseases.
###end p 3
###begin p 4
###xml 231 233 231 233 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib28">28</xref>
###xml 234 236 234 236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib30">30</xref>
###xml 511 513 511 513 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib31">31</xref>
###xml 37 43 <span type="species:ncbi:10090">murine</span>
###xml 257 262 <span type="species:ncbi:10090">mouse</span>
###xml 352 358 <span type="species:ncbi:9606">humans</span>
###xml 378 388 <span type="species:ncbi:138953">poliovirus</span>
###xml 417 423 <span type="species:ncbi:9606">humans</span>
In this study, we used the Theiler's murine encephalomyelitis virus (TMEV)-induced demyelinating disease model system, which displays immune parameters and histopathology similar to those of chronic progressive multiple sclerosis (28-30). TMEV is a natural mouse pathogen belonging to the piconavirus family, which includes many important pathogens of humans and animals; e.g., poliovirus causes paralytic disease in humans, and coxsackievirus results in mild to severe myocarditis, encephalitis, and diabetes (31). We investigated the effects of viral infection on Th17 development in vitro and in vivo, the effects of IL-17 neutralization on viral persistence in the virus target, the central nervous system (CNS), and the subsequent development of chronic demyelinating disease. In addition, we assessed the role of IL-17 in viral infection/replication and antiviral T cell cytotoxic function. Our results show that viral infection preferentially induces the development of Th17 cells, and in turn, these cells uniquely promote viral persistence via IL-17 by inhibiting apoptosis of infected cells as well as by desensitizing target cell killing by T effector cells, leading to the pathogenesis of associated chronic demyelinating disease.
###end p 4
###begin title 5
RESULTS
###end title 5
###begin title 6
Preferential induction of Th17 development by virus-infected DCs in vitro
###end title 6
###begin p 7
###xml 109 110 109 110 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 187 194 187 194 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">323-339</sub>
###xml 453 468 449 464 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1, A and B</xref>
###xml 628 636 624 632 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 A</xref>
###xml 741 749 737 745 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 B</xref>
###xml 1060 1068 1056 1064 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 C</xref>
###xml 1380 1388 1376 1384 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 D</xref>
###xml 1617 1625 1613 1621 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 D</xref>
###xml 1948 1953 1944 1949 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">74-86</sub>
###xml 2012 2013 2008 2009 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 2017 2018 2013 2014 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 2022 2025 2018 2021 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">low</sup>
###xml 2365 2370 2357 2362 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">74-86</sub>
###xml 2508 2516 2496 2504 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 E</xref>
###xml 134 149 <span type="species:ncbi:10090">transgenic mice</span>
###xml 1867 1871 <span type="species:ncbi:10090">mice</span>
To examine whether virus-infected antigen-presenting cells preferentially drive a Th17 response, purified CD4+ T cells from OT-II TCR transgenic mice specific for OVA peptide 323-339 (OVA323-339) were stimulated for 4 d with TMEV-infected BM-derived DCs (BMDCs) in the presence of the cognate peptide. Th1/Th17 cell differentiations evoked by mock- and virus-infected DCs were compared using intracellular staining of IFN-gamma and IL-17, respectively (Fig. 1, A and B). The results indicate that Th17 cell development is preferentially increased after stimulation with virus-infected DCs in an infection-dose-dependent manner (Fig. 1 A). Interestingly, paraformaldehyde-fixed virus-infected DCs failed to induce polarized Th17 development (Fig. 1 B), suggesting that the skewed Th17 development is dependent on soluble factors from virus-infected DCs. To identify cytokines involved in enhanced Th17 development, key Th1/Th17 cell differentiation-associated cytokines (IL-6, IL-12, and IL-23) produced in the supernatants of virus-infected DCs were assessed (Fig. 1 C). Notably, virus-infected DCs produced higher levels of IL-6 and IL-12p40 compared with mock-infected DCs, suggesting their possible role in elevated Th17 cell differentiation. Addition of IL-6 to the co-cultures of uninfected DCs and OT-II T cells in the presence of cognate peptide promoted Th17 development (Fig. 1 D), confirming the potential role of IL-6 in Th17 elevation. In addition, treatment of the co-cultures consisting of OT-II T cells and virus-infected DCs with neutralizing antibodies to IL-6 completely abrogated Th17 development (Fig. 1 D). These results collectively indicate that IL-6 produced by virus-infected DCs likely drives Th17 cell differentiation. To directly address the effect of viral infection on virus-specific Th17 development, we used TCR transgenic SJL/J (SJL) mice (backcross generation N14) that recognize TMEV capsid protein 2 epitope (VP274-86) (unpublished data). Naive VP2-TCR transgenic T cells (CD4+CD25-CD44low) sorted on a MoFlo cytometer (see Materials and methods) were used to assess the development of Th17 cells. Again, virus-infected SJL BMDCs preferentially supported the differentiation of Th17 cells, producing signature cytokines (IL-17 and IL-22) and an inflammatory cytokine (TNF-alpha), whereas those stimulated by BMDCs loaded with VP274-86- or UV light-inactivated TMEV (UV-TMEV) failed to generate Th17 cells despite the vigorous development of Th1 cells producing IFN-gamma (Fig. 1 E). Thus, our data clearly demonstrate that viral infection drives antigen-presenting cells to preferentially induce Th17 development in vitro.
###end p 7
###begin p 8
###xml 0 53 0 53 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Virus-infected DCs promote Th17 development in vitro.</bold>
###xml 170 177 170 177 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">323-339</sub>
###xml 475 476 475 476 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 657 664 657 664 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">323-339</sub>
###xml 842 843 842 843 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 931 932 931 932 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 936 937 936 937 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 941 944 941 944 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">low</sup>
###xml 964 965 964 965 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1000 1005 1000 1005 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">74-86</sub>
Virus-infected DCs promote Th17 development in vitro. (A) Flow cytometry of OT-II T cells cultured for 4 d with B6 BMDCs infected with varying MOIs in the presence of OVA323-339. Intracellular cytokine production was determined after restimulation with PMA plus ionomycin for 6 h. (B) Flow cytometry of OT-II T cells cultured for 4 d with TMEV-infected B6 BMDCs (MOI of 10), which were treated with PBS (unfixed) or fixed with 0.1% paraformaldehyde. Plots represent gated CD4+ T cells. (C) Cytokines produced by B6 BMDCs infected with TMEV (MOI of 10) or stimulated with LPS. **, P < 0.01 versus mock. (D) Flow cytometry of OT-II T cells stimulated with OVA323-339 in the presence of B6 BMDCs with or without IL-6, or in the presence of TMEV-infected B6 BMDCs (MOI of 10) with either isotype or anti-IL-6 antibodies. Plots represent gated CD4+ T cells. (E) Intracellular and extracellular cytokine production by isolated naive (CD4+CD25-CD44low) VP2 transgenic CD4+ T cells after stimulation with VP274-86- and UV-TMEV-pulsed or TMEV-infected SJL BMDCs. The data are a representative of three independent experiments (means +/- SD are shown in C and E). The numbers in each quadrant represent percentages. UD, undetectable.
###end p 8
###begin title 9
###xml 59 63 <span type="species:ncbi:10090">mice</span>
###xml 88 92 <span type="species:ncbi:10090">mice</span>
Elevated levels of Th17 cells in TMEV-infected susceptible mice compared with resistant mice
###end title 9
###begin p 10
###xml 347 348 347 348 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 420 428 420 428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Fig. 2 A</xref>
###xml 488 489 488 489 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 548 563 548 563 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Fig. 2, A and C</xref>
###xml 714 715 710 711 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 718 719 714 715 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 724 725 720 721 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 728 729 724 725 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 738 739 734 735 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 742 743 738 739 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 815 823 811 819 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Fig. 2 B</xref>
###xml 892 893 884 885 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1068 1069 1060 1061 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1262 1270 1254 1262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Fig. 2 C</xref>
###xml 1356 1357 1344 1345 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1425 1426 1413 1414 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1471 1479 1459 1467 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Fig. 2 C</xref>
###xml 1540 1541 1524 1525 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1612 1620 1596 1604 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Fig. 2 C</xref>
###xml 1742 1743 1726 1727 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 2023 2031 2003 2011 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Fig. 2 D</xref>
###xml 2077 2085 2053 2061 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Fig. 2 D</xref>
###xml 2125 2133 2097 2105 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Fig. 2 C</xref>
###xml 2369 2377 2341 2349 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Fig. 2 E</xref>
###xml 196 200 <span type="species:ncbi:10090">mice</span>
###xml 367 372 <span type="species:ncbi:10090">mouse</span>
###xml 542 546 <span type="species:ncbi:10090">mice</span>
###xml 809 813 <span type="species:ncbi:10090">mice</span>
###xml 917 921 <span type="species:ncbi:10090">mice</span>
###xml 1011 1015 <span type="species:ncbi:10090">mice</span>
###xml 1159 1163 <span type="species:ncbi:10090">mice</span>
###xml 1201 1205 <span type="species:ncbi:10090">mice</span>
###xml 1256 1260 <span type="species:ncbi:10090">mice</span>
###xml 1465 1469 <span type="species:ncbi:10090">mice</span>
###xml 1581 1585 <span type="species:ncbi:10090">mice</span>
###xml 1606 1610 <span type="species:ncbi:10090">mice</span>
###xml 1655 1659 <span type="species:ncbi:10090">mice</span>
###xml 2017 2021 <span type="species:ncbi:10090">mice</span>
###xml 2210 2214 <span type="species:ncbi:10090">mice</span>
###xml 2320 2324 <span type="species:ncbi:10090">mice</span>
###xml 2363 2367 <span type="species:ncbi:10090">mice</span>
###xml 2553 2557 <span type="species:ncbi:10090">mice</span>
###xml 2686 2690 <span type="species:ncbi:10090">mice</span>
To determine whether persistent viral infection fosters virus-specific Th17 responses in vivo, we analyzed levels of IL-17-producing cells in the CNS of susceptible SJL and resistant C57BL/6 (B6) mice at 8 d after TMEV infection. IL-17 production by CNS-resident microglia and infiltrated macrophages, DCs, granulocytes, B cells, and cytotoxic CD8+ T cells from both mouse strains was either undetectable or negligible (Fig. 2 A). However, low but detectable levels of IL-17-producing CD4+ T cells were found in virus-infected SJL but not B6 mice (Fig. 2, A and C). To confirm these flow cytometry results, we assessed mRNA levels of IL-17 and the Th17 lineage-specific transcription factor RORgammat in sorted CD4+CD8-, CD4-CD8+, and CD4-CD8- CNS-infiltrating mononuclear cells from TMEV-infected SJL and B6 mice (Fig. 2 B). Both IL-17 and RORgammat mRNAs were primarily expressed by the CD4+ T cell fraction of SJL mice compared with other SJL cellular fractions (P < 0.001) or CNS-infiltrating cells from B6 mice (P < 0.001). These results clearly indicate that CD4+ T cells are the predominant source of IL-17 in the CNS of virus-infected susceptible SJL mice. Th17 cell numbers in the CNS of SJL mice were as much as 100-fold greater than those of B6 mice (Fig. 2 C, bottom). In contrast, no difference in the overall number of IFN-gamma-producing CD4+ T cells between these strains was found as a result of elevated CD4+ T cell infiltration to the CNS in SJL mice (Fig. 2 C, bottom), although the proportion of IFN-gamma-producing CD4+ T cells was lower in TMEV-infected SJL mice in comparison to B6 mice (Fig. 2 C, top). Th17 cells in infected SJL mice appear to be viral antigen specific, because similar levels of IL-17-producing CD4+ T cells were found after in vitro stimulation with anti-CD3/CD28 versus UV-TMEV (Fig. S1, available at ). Upon restimulation of CNS-infiltrating cells with UV-TMEV ex vivo, significantly higher levels of IL-17 and lower levels of IFN-gamma were detected from SJL versus B6 mice (Fig. 2 D). This discrepancy between IFN-gamma levels (Fig. 2 D) and IFN-gamma-producing cell numbers (Fig. 2 C) may reflect differences in cytokine levels produced per cell by SJL and B6 mice. It is interesting to note that IL-6 is detectable only in the CNS (both brains and spinal cords) of SJL mice during viral infection, but not in B6 mice (Fig. 2 E), strongly suggesting that this cytokine plays a key role in Th17 development and expansion. Collectively, these observations indicate that viral infection in susceptible SJL mice results in the preferential development of Th17 responses, along with low levels of Th1 responses as compared with resistant B6 mice.
###end p 10
###begin p 11
###xml 0 68 0 68 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Th17 development is elevated in virus-infected susceptible SJL mice.</bold>
###xml 164 165 164 165 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 343 344 339 340 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 347 348 343 344 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 353 354 349 350 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 357 358 353 354 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 367 368 363 364 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 371 372 367 368 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 471 472 467 468 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 659 660 655 656 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 741 742 737 738 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 852 853 848 849 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 987 988 979 980 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1157 1158 1149 1150 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 63 67 <span type="species:ncbi:10090">mice</span>
###xml 158 162 <span type="species:ncbi:10090">mice</span>
###xml 465 469 <span type="species:ncbi:10090">mice</span>
###xml 577 581 <span type="species:ncbi:10090">mice</span>
###xml 653 657 <span type="species:ncbi:10090">mice</span>
###xml 894 898 <span type="species:ncbi:10090">mice</span>
###xml 981 985 <span type="species:ncbi:10090">mice</span>
###xml 1104 1108 <span type="species:ncbi:10090">mice</span>
###xml 1151 1155 <span type="species:ncbi:10090">mice</span>
###xml 1219 1223 <span type="species:ncbi:10090">mice</span>
Th17 development is elevated in virus-infected susceptible SJL mice. (A) Intracellular IL-17 analysis of CNS mononuclear cells from virus-infected SJL and B6 mice (n = 3) after stimulation with PMA plus ionomycin. The number in each plot shows the proportion of IL-17-producing cells. (B) Induction of IL-17 and RORgammat mRNAs in isolated CD4+CD8-, CD4-CD8+, and CD4-CD8- CNS mononuclear cells relative to GAPDH mRNA. Isolation of cell populations from SJL and B6 mice (n = 6) at 8 d after TMEV infection was achieved using a MoFlo cytometer. ***, P < 0.001 for SJL versus B6 mice. (C) Flow cytometry of SJL and B6 CNS-infiltrating cells from infected mice (n = 3), followed by stimulation with PMA plus ionomycin. Each plot is gated on CD4+ T cells (percentages are shown). The bar graphs depict cell numbers of cytokine-secreting CNS-infiltrated CD4+ T cells. **, P < 0.01 for SJL versus B6 mice. (D) ELISA of IL-17 and IFN-gamma produced by CNS-infiltrated cells isolated from mice (n = 3) at 8 d after TMEV infection after stimulation with different doses of UV-TMEV. **, P < 0.01 for SJL versus B6 mice. (E) IL-6 levels in the CNS of SJL and B6 mice (n = 3) were measured by ELISA. **, P < 0.01 for SJL versus B6 mice. Data presented in A and C-E are representative of three independent experiments, and the results in B represent one out of two independent experiments (means +/- SD are shown in B-E). UD, undetectable.
###end p 11
###begin title 12
###xml 52 56 <span type="species:ncbi:10090">mice</span>
IL-6-dependent elevation of Th17 cell numbers in B6 mice after TMEV infection in conjunction with LPS treatment
###end title 12
###begin p 13
###xml 255 257 255 257 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib32">32</xref>
###xml 536 551 536 551 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3, A and B</xref>
###xml 587 588 587 588 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 700 708 700 708 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3 C</xref>
###xml 782 783 778 779 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 968 976 964 972 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3 D</xref>
###xml 1068 1070 1064 1066 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib10">10</xref>
###xml 1578 1579 1574 1575 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1760 1768 1756 1764 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3 E</xref>
###xml 1989 1990 1981 1982 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib2">2</xref>
###xml 1992 1993 1984 1985 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib4">4</xref>
###xml 2276 2291 2268 2283 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3, F and G</xref>
###xml 2344 2345 2332 2333 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 2490 2498 2478 2486 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3 F</xref>
###xml 2673 2681 2661 2669 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3 G</xref>
###xml 147 151 <span type="species:ncbi:10090">mice</span>
###xml 356 360 <span type="species:ncbi:10090">mice</span>
###xml 530 534 <span type="species:ncbi:10090">mice</span>
###xml 623 627 <span type="species:ncbi:10090">mice</span>
###xml 694 698 <span type="species:ncbi:10090">mice</span>
###xml 835 839 <span type="species:ncbi:10090">mice</span>
###xml 853 857 <span type="species:ncbi:10090">mice</span>
###xml 1405 1409 <span type="species:ncbi:10090">mice</span>
###xml 1456 1460 <span type="species:ncbi:10090">mice</span>
###xml 1535 1539 <span type="species:ncbi:10090">mice</span>
###xml 2064 2068 <span type="species:ncbi:10090">mice</span>
###xml 2183 2187 <span type="species:ncbi:10090">mice</span>
###xml 2270 2274 <span type="species:ncbi:10090">mice</span>
###xml 2412 2416 <span type="species:ncbi:10090">mice</span>
###xml 2484 2488 <span type="species:ncbi:10090">mice</span>
###xml 2561 2565 <span type="species:ncbi:10090">mice</span>
###xml 2667 2671 <span type="species:ncbi:10090">mice</span>
###xml 2836 2840 <span type="species:ncbi:10090">mice</span>
To further correlate the observed increase in Th17 development with susceptibility to TMEV-induced demyelinating disease, we rendered resistant B6 mice susceptible by administration of the Gram-negative endotoxin LPS, as demonstrated in our earlier work (32). Intraperitoneal injection of LPS, concomitant with intracerebral TMEV infection in resistant B6 mice, resulted in persistent infection as well as clinical symptoms, whereas no detectable disease development and low viral persistence were observed in control PBS-treated mice (Fig. 3, A and B). The number of IL-17-producing CD4+ T cells in the CNS of LPS-treated mice was increased >300-fold compared with that of control PBS-treated mice (Fig. 3 C). In contrast, similar proportions and numbers of IFN-gamma-producing CD4+ T cells were observed between LPS- and PBS-treated mice. LPS-treated mice exhibited significantly higher levels of IL-6 in particular, as well as CXCL1/KC and CCL2/MCP-1 in the brain (Fig. 3 D). These cytokines and chemokines are known to be associated with IL-17 signaling pathways (10). These results are consistent with in vitro observations that the treatment of BMDCs with LPS significantly enhances the induction of Th17 cells as compared with treatment with PBS (Fig. S2, available at ). Thus, LPS treatment appears to be a prerequisite for Th17 elevation to the pathogenic threshold in TMEV-infected resistant B6 mice, in contrast to TMEV-infected susceptible SJL mice that generate a high level of Th17 cells. Th17 cells found in LPS-treated mice appear to represent virus-specific CD4+ T cells, because IL-17 production by peripheral splenocytes was observed in response to MHC class II-restricted viral epitopes or UV-TMEV, but not MHC class I-restricted epitopes (Fig. 3 E). In contrast, levels of viral antigen-specific IFN-gamma responses were similar in both the virus-infected PBS- and LPS-treated groups. Because it was previously reported that Th1 responses antagonize Th17 development (2, 4), finding similar levels of Th1 cells in both groups of TMEV-infected mice was unexpected. To further determine the role of IL-6 in the increased generation of Th17 cells in virus-infected mice, we compared levels of Th17 cells in virus-infected LPS-treated WT and IL-6 KO B6 mice (Fig. 3, F and G). Although similar levels of IFN-gamma-producing CD4+ T cells were observed in the CNS of virus-infected WT and IL-6 KO mice, the development of Th17 cells in the CNS was abrogated in IL-6 KO mice (Fig. 3 F). In addition, viral titers in the CNS of LPS-treated IL-6 KO mice were significantly lower at days 8 and 21 after TMEV infection compared with those of LPS-treated WT mice (Fig. 3 G). Collectively, these results clearly demonstrate that both viral persistence and the development of TMEV-induced demyelinating disease in LPS-treated B6 mice strongly correlate with elevated Th17 cell levels in the CNS in an IL-6-dependent manner.
###end p 13
###begin p 14
###xml 0 136 0 136 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Virus infection in conjunction with bacterial endotoxin administration promotes Th17 development in resistant B6 mice via elevated IL-6.</bold>
###xml 227 228 227 228 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 243 244 243 244 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 711 712 711 712 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 799 800 799 800 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1505 1506 1501 1502 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1602 1603 1598 1599 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 113 117 <span type="species:ncbi:10090">mice</span>
###xml 144 148 <span type="species:ncbi:10090">mice</span>
###xml 494 498 <span type="species:ncbi:10090">mice</span>
###xml 638 642 <span type="species:ncbi:10090">mice</span>
###xml 978 982 <span type="species:ncbi:10090">mice</span>
###xml 1148 1152 <span type="species:ncbi:10090">mice</span>
###xml 1405 1409 <span type="species:ncbi:10090">mice</span>
###xml 1703 1707 <span type="species:ncbi:10090">mice</span>
###xml 1855 1859 <span type="species:ncbi:10090">mice</span>
Virus infection in conjunction with bacterial endotoxin administration promotes Th17 development in resistant B6 mice via elevated IL-6. (A) B6 mice were infected with TMEV in conjunction with intraperitoneal injection of PBS (n = 10) or LPS (n = 10), and the development of demyelinating disease was monitored. One representative out of three independent experiments is shown. (B) Levels of infectious virus in the CNS were quantified 8 and 21 d after TMEV infection in PBS- or LPS-treated B6 mice. *, P < 0.05 between LPS- and PBS-treated groups. (C) CNS-infiltrating cells obtained at 8 d after TMEV infection from PBS- or LPS-treated mice were restimulated with PMA plus ionomycin. Plots represent gated CD4+ T cells (percentages are shown), and the graph shows numbers of cytokine-secreting CD4+ T cells. **, P < 0.01 between LPS- and PBS-treated groups. (D) Levels of IL-6, KC, and MCP-1 in brains were measured using ELISA 8 d after TMEV infection in PBS- or LPS-treated mice. **, P < 0.01 between LPS- and PBS-treated groups. (E) IFN-gamma and IL-17 levels produced by splenocytes isolated from PBS- (TMEV/PBS) or LPS-treated (TMEV/LPS) B6 mice 8 d after mock or TMEV infection were assessed using ELISA after restimulation with mixed CD4 epitopes, UV-TMEV, or mixed CD8 epitopes. **, P < 0.01 between LPS- and PBS-treated groups. (F) CNS mononuclear cells isolated from LPS-treated WT or IL-6 KO mice at 8 d after TMEV infection were restimulated with PMA plus ionomycin. All plots show gated CD4+ T cells (percentages are shown), and the bar graphs represent numbers of cytokine-producing CD4+ T cells. **, P < 0.01 between WT and IL-6 KO groups. (G) Viral titers in the CNS of WT and IL-6 KO mice 8 and 21 d after infection are shown. *, P < 0.05 between WT and IL-6 KO groups. Results in B-G represent values from pooled CNS or spleens of two mice per group and are representative examples of three separate experiments (means +/- SD are shown). UD, undetectable.
###end p 14
###begin title 15
Treatment with antibodies to IL-17 inhibits viral persistence and disease development
###end title 15
###begin p 16
###xml 237 238 237 238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib4">4</xref>
###xml 240 242 240 242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib11">11</xref>
###xml 570 581 570 581 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4, A&#8211;F</xref>
###xml 1085 1093 1081 1089 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4 A</xref>
###xml 1228 1230 1224 1226 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">hi</sup>
###xml 1250 1252 1246 1248 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">hi</sup>
###xml 1257 1258 1253 1254 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1492 1507 1488 1503 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4, B and C</xref>
###xml 1629 1630 1621 1622 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1640 1648 1632 1640 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4 D</xref>
###xml 1681 1682 1669 1670 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 2011 2019 1999 2007 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4 E</xref>
###xml 2228 2236 2216 2224 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4 F</xref>
###xml 2264 2272 2252 2260 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4 G</xref>
###xml 2938 2946 2926 2934 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4 F</xref>
###xml 2986 2994 2974 2982 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4 G</xref>
###xml 211 216 <span type="species:ncbi:9606">human</span>
###xml 516 520 <span type="species:ncbi:10090">mice</span>
###xml 1046 1050 <span type="species:ncbi:10090">mice</span>
###xml 1448 1452 <span type="species:ncbi:10090">mice</span>
###xml 1486 1490 <span type="species:ncbi:10090">mice</span>
###xml 1586 1590 <span type="species:ncbi:10090">mice</span>
###xml 1844 1848 <span type="species:ncbi:10090">mice</span>
###xml 2258 2262 <span type="species:ncbi:10090">mice</span>
###xml 2595 2599 <span type="species:ncbi:10090">mice</span>
###xml 2883 2887 <span type="species:ncbi:10090">mice</span>
###xml 2980 2984 <span type="species:ncbi:10090">mice</span>
Recent reports indicate that Th17 cells and their cytokine IL-17 play a pivotal role in tissue inflammation and damage, causing CNS demyelination in experimental autoimmune encephalomyelitis and perhaps also in human multiple sclerosis (4, 11). To determine whether this T cell type is also involved in the establishment of viral persistence and the consequent pathogenesis of chronic demyelinating disease, either neutralizing anti-IL-17 antibodies or isotype control antibodies were administered to LPS-treated B6 mice at days 0, 7, and 14 relative to TMEV infection (Fig. 4, A-F). Treatment with anti-IL-17 antibody reduced serum IL-17 to nearly undetectable levels during acute viral infection (8 d after infection) compared with treatment with isotype antibody, indicating the effectiveness of neutralizing antibodies (Fig. S3 A, available at ). Interestingly, IFN-gamma and IL-17 levels produced by splenocytes in response to CD4 epitopes, UV-TMEV, and CD8 epitopes in the control group treated with isotype antibodies were comparable with mice treated with anti-IL-17 antibody (Fig. 4 A), suggesting that anti-IL-17 antibody treatment neutralizes IL-17 without eliminating Th17 cells. However, cellular infiltration (CD45hi leukocytes and CD45hiCD11b+ macrophages) to the CNS was decreased by more than twofold at day 8 after infection. Levels of Th17-associated IL-6, KC, and MCP-1 were also lower in the CNS of anti-IL-17 antibody-treated mice than in isotype antibody-treated mice (Fig. 4, B and C). Despite low levels of leukocyte infiltration in anti-IL-17 antibody-treated mice, IFN-gamma and IL-17 production by CD4+ T cells (Fig. 4 D) and IFN-gamma production by CD8+ T cells (Fig. S3 B) in the CNS were uncompromised. We further analyzed whether TMEV persists and induces chronic demyelinating disease in these antibody-treated mice. Viral persistence in the CNS was significantly lower at days 8 and 21 after infection in the anti-IL-17-treated group versus the control antibody-treated group (Fig. 4 E and Fig. S4 C). Furthermore, drastic reductions (P < 0.01) in the incidence and severity of demyelinating disease were observed in the anti-IL-17-treated group compared with control groups of LPS-treated B6 (Fig. 4 F) and susceptible SJL mice (Fig. 4 G). Histological examinations of these anti-IL-17 antibody-treated groups displayed very little cellular infiltration and demyelination in spinal cords, in contrast to extensive demyelination and cellular infiltration in isotype control groups (Fig. S4, A and B). Thus, the elimination of IL-17 function from virus-infected mice appears to prevent the development of demyelinating disease. These results clearly indicate that IL-17 plays a critical pathogenic role in the establishment of viral persistence and pathogenesis of chronic demyelinating disease in both temporarily converted genetically resistant B6 mice that have become susceptible after LPS treatment (Fig. 4 F) and genetically susceptible SJL mice (Fig. 4 G).
###end p 16
###begin p 17
###xml 0 115 0 115 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Treatment of mice with anti&#8211;IL-17 antibody inhibits viral persistence and the development of demyelinating disease.</bold>
###xml 614 616 610 612 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">hi</sup>
###xml 636 638 632 634 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">hi</sup>
###xml 643 644 639 640 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1025 1026 1021 1022 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1113 1114 1109 1110 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1715 1716 1709 1710 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1737 1738 1731 1732 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 13 17 <span type="species:ncbi:10090">mice</span>
###xml 140 144 <span type="species:ncbi:10090">mice</span>
###xml 509 513 <span type="species:ncbi:10090">mice</span>
###xml 798 802 <span type="species:ncbi:10090">mice</span>
###xml 1489 1493 <span type="species:ncbi:10090">mice</span>
###xml 1611 1615 <span type="species:ncbi:10090">mice</span>
###xml 1645 1649 <span type="species:ncbi:10090">mice</span>
Treatment of mice with anti-IL-17 antibody inhibits viral persistence and the development of demyelinating disease. (A) Splenocytes from B6 mice treated with PBS alone, LPS and isotype control antibody (TMEV/LPS/Isotype Abs), or anti-IL-17 antibody (TMEV/LPS/alphaIL-17 Abs) 8 d after mock or TMEV infection were restimulated with mixed CD4 epitopes, UV-TMEV, or mixed CD8 epitopes. Cytokines produced in culture supernatants were analyzed using ELISA. (B) Flow cytometry of CNS-infiltrating cells from these mice at 8 d after infection (percentages are shown). The bar graph shows numbers of CNS-infiltrating CD45hi leukocytes and CD45hiCD11b+ macrophages. ***, P < 0.001 for anti-IL-17 versus isotype antibody-treated groups. (C) Levels of IL-6, KC, and MCP-1 in the brains from TMEV-infected B6 mice. **, P < 0.01; and ***, P < 0.001 for anti-IL-17 versus isotype antibody groups. (D) Intracellular cytokine production by CNS-infiltrating cells after restimulation with PMA plus ionomycin. All flow plots display gated CD4+ T cells (percentages are shown). The bar graph shows numbers of cytokine-secreting CD4+ T cells. ***, P < 0.001 between groups treated with anti-IL-17 and isotype control antibodies. (E) Viral persistence levels in the CNS 8 and 21 d after infection were determined by plaque assay. *, P < 0.05; and ***, P < 0.001 between anti-IL-17 and isotype control groups. Data in A-E represent values from a single experiment conducted with pools of spleens or CNS of two mice per group (means +/- SD are shown). Three independent experiments were performed to verify the results. (F and G) B6 mice treated with LPS (F) and SJL mice (G) were infected with TMEV in conjunction with isotype control (n = 9) or anti-IL-17 (n = 9) antibody treatment. The effects of anti-IL-17 antibody treatment on disease development were confirmed once by separate experiments (means +/- SD are shown).
###end p 17
###begin title 18
IL-17 augments the production of virus-induced IL-6, KC, and MCP-1 in permissive cells and protects virus-infected cells from apoptosis
###end title 18
###begin p 19
###xml 176 182 176 182 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4</xref>
###xml 338 344 338 344 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Fig. 5</xref>
###xml 454 455 454 455 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 512 527 508 523 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Fig. 5, A and C</xref>
###xml 628 643 624 639 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Fig. 5, A and C</xref>
###xml 923 938 919 934 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Fig. 5, B and D</xref>
###xml 1133 1135 1129 1131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib10">10</xref>
###xml 1137 1139 1133 1135 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib33">33</xref>
###xml 1284 1292 1280 1288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Fig. 5 E</xref>
###xml 1517 1519 1513 1515 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib34">34</xref>
###xml 1421 1425 <span type="species:ncbi:10090">mice</span>
Because the above observations suggest that IL-17 plays an important role in promoting viral persistence and the consequent pathogenesis of inflammatory demyelinating disease (Fig. 4), we next determined whether or not IL-17 is able to directly enhance viral replication and inflammatory mediator production in permissive cells in vitro (Fig. 5). As expected, a marked reduction of TMEV infection/replication at 24 h after infection was observed in CD11c+ BMDCs and primary astrocytes pretreated with IFN-gamma (Fig. 5, A and C). However, viral infection/replication levels were similar in IL-17-pretreated and untreated cells (Fig. 5, A and C). Despite similar levels of viral replication in IL-17-pretreated and untreated cultures, the production of IL-6, KC, and MCP-1, but not IL-12p40, was markedly increased in both IL-17-treated DCs and astrocytes after TMEV infection as compared with control PBS-treated cultures (Fig. 5, B and D). Thus, these increases in cytokines and chemokines likely participate in further augmenting Th17 development and selective cellular infiltration in the virus target organ, as previously shown (10, 33). Furthermore, IL-17 treatment significantly inhibited virus-induced apoptosis of BM cells and primary astrocytes but not differentiated BMDCs (Fig. 5 E). Consequently, this IL-17-mediated protection against apoptosis likely promotes viral persistence in the CNS of virus-infected mice, as shown with an increase in virus yield by inhibiting apoptosis of virus-infected cells (34). The failure of IL-17 treatment to protect BMDCs from apoptosis was not caused by the lack of IL-17R expression (Fig. S5 A, available at ), suggesting the involvement of other factors in this protection. Interestingly, IL-17-mediated protection of BM cells appears to be restricted to certain inducers, as apoptosis induced by dexamethasone and anti-Fas mAb using the caspase 8 pathway, but not C2-ceramide and UV irradiation using alternative pathways, was inhibited (Fig. S5 B). Collectively, these findings indicate that IL-17 augments inflammatory responses by amplifying the production of proinflammatory cytokines and protecting virus-infected cells from apoptotic death.
###end p 19
###begin p 20
###xml 0 120 0 120 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL-17 enhances virus-induced production of inflammatory cytokines and protects against infection-induced cell apoptosis.</bold>
###xml 1198 1202 1192 1196 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">high</sup>
IL-17 enhances virus-induced production of inflammatory cytokines and protects against infection-induced cell apoptosis. (A-D) B6 BMDCs (A) and astrocytes (C) pretreated with IL-17 or IFN-gamma for 6 h were infected with TMEV for 24 h. Levels of viral infection were assessed using flow cytometry after staining with anti-TMEV antibody or plaque assay with culture supernatants of TMEV-infected cells. The numbers in each quadrant represent percentages. UD, undetectable values <100 PFU/ml. (C) Histograms represent astrocytes stained with isotype control (red) and anti-TMEV antibody (open). Cytokine levels in B6 BMDCs (B) and astrocytes (D) infected with TMEV for 24 h in the presence of PBS or IL-17 were measured using ELISA. UD, undetectable values <10 pg/ml. *, P < 0.05; **, P < 0.01; and ***, P < 0.001 for IL-17- versus PBS-treated cultures. Data in A-D are representative of four separate experiments (means +/- SD are shown). (E) TMEV infection-induced cell apoptosis was determined using flow cytometry of BM cells (2-d culture), BMDCs (5-d culture), and neonatal astrocytes 24 h after coincubation with PBS or IL-17. The number in each histogram represents the percentage of Annexin Vhigh cells. The graph shows data from three independent experiments. The horizontal bar represents the mean of the group. **, P < 0.01; and ***, P < 0.001 between IL-17- versus PBS-treated cultures.
###end p 20
###begin title 21
IL-17 inhibits antiviral cytotoxic T cell function in vitro
###end title 21
###begin p 22
###xml 60 61 60 61 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 183 189 183 189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4</xref>
###xml 272 273 272 273 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 591 598 591 598 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">121-130</sub>
###xml 668 669 668 669 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 832 840 832 840 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig6">Fig. 6 A</xref>
###xml 939 940 935 936 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 950 958 946 954 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig6">Fig. 6 B</xref>
###xml 1045 1047 1041 1043 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib35">35</xref>
###xml 1092 1100 1088 1096 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig6">Fig. 6 C</xref>
###xml 1156 1158 1152 1154 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib36">36</xref>
###xml 1269 1277 1265 1273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig6">Fig. 6 C</xref>
###xml 1345 1346 1341 1342 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1562 1570 1558 1566 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig6">Fig. 6 D</xref>
###xml 1643 1644 1639 1640 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1717 1718 1713 1714 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1972 1980 1968 1976 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig6">Fig. 6 E</xref>
###xml 2045 2046 2041 2042 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 2177 2178 2173 2174 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 2240 2248 2236 2244 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig6">Fig. 6 E</xref>
###xml 112 116 <span type="species:ncbi:10090">mice</span>
###xml 392 396 <span type="species:ncbi:10090">mice</span>
###xml 1823 1828 <span type="species:ncbi:9606">human</span>
The potential roles of Th17 cells and IL-17 on cytotoxic CD8+ T cell function are unknown. Because treatment of mice with anti-IL-17 antibodies enhances viral clearance from the CNS (Fig. 4), we explored the possibility that IL-17 compromises the cytotoxic function of CD8+ T cells, which are the key host defense immune mechanism against viral infections. Splenocytes from virus-infected B6 mice at the peak of acute infection were pretreated for 24 h or treated simultaneously with IL-17 and then assessed for cytolytic function with a typical short-term (6-h) cytotoxicity assay using VP2121-130-loaded EL-4 target cells. Although the specific lytic activity of CD8+ T cells was slightly lower (not statistically significant) after pretreatment with IL-17 for 24 h, it remained unchanged after simultaneous treatment with IL-17 (Fig. 6 A). Similarly, IL-17 treatment did not significantly alter levels of granzyme B and IFN-gamma on CD8+ T cells (Fig. 6 B). In contrast, IL-17, but not IL-17F, which has a high degree of homology with IL-17 (35), abrogated the slow (60-h) lytic reaction (Fig. 6 C) that is prominently mediated by the Fas-FasL pathway (36). This lytic reaction was similarly inhibited with IL-17 pretreatment of target cells but not effector cells (Fig. 6 C), indicating that IL-17 treatment impedes cytolytic function of CD8+ T cells through signaling on target cells. To determine whether IL-17 inhibits cytotoxic function by blocking apoptosis of target cells during long-term cytolytic reactions, levels of apoptotic cells were analyzed (Fig. 6 D). The results showed that target cells are completely protected from CD8+ T cell-mediated apoptosis in the presence of IL-17, whereas effector CD8+ T cells remain unaltered. We further assessed the effects of an inhibitor of Fas-FasL interaction using human Fas:Fc (Fas-IgG Fc fusion protein) on IL-17-mediated inhibition of cytotoxic function to confirm the involvement of the Fas-dependent pathway (Fig. 6 E). The addition of Fas:Fc protein dramatically inhibited slow CD8+ T cell-mediated lysis in the absence of IL-17 but not in the presence of IL-17, strongly suggesting that IL-17 interferes with CD8+ T cell cytotoxic function via blocking the Fas-FasL pathway (Fig. 6 E), consistent with the inhibition of anti-Fas antibody-induced apoptosis by IL-17 (Fig. S5).
###end p 22
###begin p 23
###xml 0 51 0 51 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL-17 inhibits antiviral cytotoxic T cell function.</bold>
###xml 240 242 240 242 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">51</sup>
###xml 268 275 268 275 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">121-130</sub>
###xml 435 442 435 442 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">121-130</sub>
###xml 590 591 586 587 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 656 663 652 659 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">121-130</sub>
###xml 670 677 666 673 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">323-339</sub>
###xml 1026 1033 1022 1029 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">121-130</sub>
###xml 1050 1057 1046 1053 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">323-339</sub>
###xml 1580 1581 1576 1577 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1853 1854 1849 1850 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1859 1860 1855 1856 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 76 80 <span type="species:ncbi:10090">mice</span>
###xml 357 361 <span type="species:ncbi:10090">mice</span>
###xml 631 635 <span type="species:ncbi:10090">mice</span>
###xml 1996 2000 <span type="species:ncbi:10090">mice</span>
IL-17 inhibits antiviral cytotoxic T cell function. (A) Splenocytes from B6 mice at 8 d after infection were pretreated for 24 h or were simultaneously treated with IL-17 (IL-17 Pre or IL-17 Sim, respectively), and were then subjected to a 51Cr-release assay using VP2121-130-loaded EL-4 target cells. (B) Splenocytes (effector cells) from TMEV-infected B6 mice were co-cultured with naive B6 splenocytes (target cells) loaded with VP2121-130 for 24 h in the presence of IL-17 at an E/T ratio of 10:1. The numbers in the plots indicate the frequency of granzyme B- or IFN-gamma-positive CD8+ T cells. (C) Splenocytes from naive B6 mice were loaded with VP2121-130 or OVA323-339 peptides and labeled with a lower or higher concentration of CFSE, respectively, as target cells. The labeled target and effector cells were pretreated separately with IL-17 for 24 h and co-cultured or cultured together in the presence of IL-17F or IL-17 for an additional 60 h. The numbers in each histogram represent percentages of the lower (VP2121-130) and higher (OVA323-339) concentrations of CFSE-labeled cells. The arrow shows the specific killing of target cells. (D) Apoptosis levels of effector and target cells from the cultures in C at an E/T ratio of 10:1 were assessed after a 24-h incubation (percentages are shown). (E) Levels of target cell destruction in the presence of Fas:Fc were assessed 60 h after co-culture with effector cells at an E/T ratio of 30:1 (percentages are shown). The arrows show virus-specific killing. (F) Levels of antigen-loaded B cell killing by activated CD4+ T cells were determined. Peptide-loaded B cells were co-cultured in the presence of LPS and PBS or IL-17 at a 1:5 ratio for 24 h with effector OT-II T cells that were preactivated with anti-CD3/CD28 antibodies. The numbers in each plot indicate the frequency of Annexin V+ B220+ B cells. (G) Intracellular expression levels of Bcl-xl and Bcl-2 proteins in LPS-stimulated B cells, BM cells, and BMDCs from naive B6 mice were assessed after a 24-h incubation with PBS (shaded histogram) or IL-17 (open histogram). Relative median fluorescence intensity differences between the IL-17 and the PBS group are illustrated on the flow histograms. Data are representative of four independent experiments.
###end p 23
###begin p 24
###xml 64 65 64 65 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 128 129 128 129 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 212 214 212 214 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib37">37</xref>
###xml 216 218 216 218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib38">38</xref>
###xml 309 310 309 310 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 473 480 473 480 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">323-339</sub>
###xml 542 543 542 543 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 553 561 553 561 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig6">Fig. 6 F</xref>
###xml 814 822 814 822 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig6">Fig. 6 G</xref>
###xml 949 957 949 957 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig6">Fig. 6 G</xref>
We further examined whether IL-17 exerts a similar effect on CD4+ T cell-mediated apoptosis, because MHC class II-restricted CD4+ T cell-mediated killing of target cells during viral infection has been reported (37, 38). We used the OT-II TCR transgenic system to address the effects of IL-17 treatment on CD4+ T cell-mediated killing of epitope peptide-loaded target B cells. Again, the presence of IL-17 significantly (greater than twofold) inhibited the apoptosis of OVA323-339-loaded B cells induced by cognate interactions with OT-II CD4+ T cells (Fig. 6 F). To further understand the underlying mechanisms for protection of immune target cells by IL-17, expression levels of prosurvival B cell lymphoma-xl (Bcl-xl) and Bcl-2 proteins in B cells, BM cells, and BMDCs were assessed after treatment with IL-17 (Fig. 6 G). B cells and BM cells, but not BMDCs, displayed elevated expression of both Bcl-xl and Bcl-2 in response to IL-17 treatment (Fig. 6 G), suggesting that IL-17-induced up-regulation of prosurvival protein expression contributes to the protection of target cells from effector T cell-mediated killing. Thus, IL-17 apparently inhibits antiviral cytotoxic T cell function in vitro by protecting target cells from effector T cell-induced apoptosis.
###end p 24
###begin title 25
###xml 28 32 <span type="species:ncbi:10090">mice</span>
Anti-IL-17 antibody-treated mice display enhanced antiviral cytotoxic T cell function in vivo
###end title 25
###begin p 26
###xml 93 99 93 99 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig6">Fig. 6</xref>
###xml 540 548 540 548 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig7">Fig. 7 A</xref>
###xml 648 649 648 649 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib5">5</xref>
###xml 791 799 791 799 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig7">Fig. 7 A</xref>
###xml 1016 1024 1016 1024 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig7">Fig. 7 B</xref>
###xml 1112 1113 1112 1113 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1121 1122 1121 1122 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1132 1140 1132 1140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig7">Fig. 7 C</xref>
###xml 1386 1387 1386 1387 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1496 1497 1496 1497 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1632 1640 1628 1636 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig7">Fig. 7 D</xref>
###xml 1705 1706 1701 1702 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 2032 2040 2028 2036 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig7">Fig. 7 E</xref>
###xml 130 134 <span type="species:ncbi:10090">mice</span>
###xml 235 239 <span type="species:ncbi:10090">mice</span>
###xml 496 500 <span type="species:ncbi:10090">mice</span>
###xml 534 538 <span type="species:ncbi:10090">mice</span>
###xml 785 789 <span type="species:ncbi:10090">mice</span>
###xml 966 970 <span type="species:ncbi:10090">mice</span>
###xml 1010 1014 <span type="species:ncbi:10090">mice</span>
###xml 1227 1231 <span type="species:ncbi:10090">mice</span>
###xml 1319 1323 <span type="species:ncbi:10090">mice</span>
###xml 1757 1761 <span type="species:ncbi:10090">mice</span>
###xml 1834 1838 <span type="species:ncbi:10090">mice</span>
###xml 1915 1919 <span type="species:ncbi:10090">mice</span>
###xml 2069 2073 <span type="species:ncbi:10090">mice</span>
To correlate the above in vitro results of enhanced target cell survival by IL-17 treatment (Fig. 6) with those in virus-infected mice in vivo, we sought to examine whether administration of anti-IL-17 antibody into virus-infected SJL mice reduces the number of virus-permissive cells in the target organ (CNS) and enhances antiviral cytotoxic T cell function. 8 d after infection, the proportion and number of CNS-infiltrating macrophages were significantly lower in anti-IL-17 antibody-treated mice than in isotype antibody-treated mice (Fig. 7 A), suggesting that cellular infiltration is affected by antibody treatment, as previously reported (5). In contrast, a similar proportion and number of CNS-resident microglia were observed in both anti-IL-17 and isotype antibody-treated mice (Fig. 7 A). Notably, the expression of prosurvival Bcl-xl and Bcl-2 proteins in both infiltrating macrophages and resident microglia was reduced in anti-IL-17 antibody-treated mice compared with isotype antibody-treated mice (Fig. 7 B). This reduction of antiapoptotic proteins was not detectable in antiviral effector CD4+ and CD8+ T cells (Fig. 7 C). These results indicate that virus-permissive cells from anti-IL-17 antibody-treated mice became more susceptible to apoptosis. If this is the case, anti-IL-17 antibody-treated mice would be expected to develop low numbers of virus-specific CD8+ T cells corresponding to their limited viral load. To examine this possibility, levels of virus-specific CD8+ T cells were assessed using intracellular IFN-gamma staining after in vitro restimulation with dominant and subdominant VP3 epitopes (Fig. 7 D). The results indicate that the proportion of virus-specific CD8+ T cells in the CNS of anti-IL-17 antibody-treated mice is higher yet the overall number is lower compared with isotype-treated mice. To further analyze antiviral cytotoxic T cell function in antibody-treated mice, in vivo lytic responses to target cells loaded with dominant and subdominant viral epitopes were investigated (Fig. 7 E). TMEV-infected susceptible mice treated with anti-IL-17 antibody displayed significantly increased elimination of newly introduced viral epitope peptide-loaded target cells. Collectively, these results clearly indicate that anti-IL-17 antibody treatment enhances the function of antiviral cytotoxic T cells by facilitating the removal of virus-infected target cells during viral infection, leading to efficient viral clearance and, consequently, reduced disease development.
###end p 26
###begin p 27
###xml 0 103 0 103 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Treatment of virus-infected mice with anti&#8211;IL-17 antibody elevates antiviral cytotoxic T cell function.</bold>
###xml 312 314 312 314 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">hi</sup>
###xml 319 320 319 320 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 350 353 350 353 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">int</sup>
###xml 358 359 358 359 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 557 558 557 558 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 566 567 566 567 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1130 1131 1126 1127 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1223 1224 1215 1216 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1503 1510 1493 1500 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">159-166</sub>
###xml 1539 1546 1529 1536 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">173-181</sub>
###xml 1670 1671 1660 1661 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1692 1693 1682 1683 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1847 1848 1837 1838 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 2021 2028 2011 2018 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">323-339</sub>
###xml 28 32 <span type="species:ncbi:10090">mice</span>
###xml 158 162 <span type="species:ncbi:10090">mice</span>
###xml 598 602 <span type="species:ncbi:10090">mice</span>
###xml 1035 1039 <span type="species:ncbi:10090">mice</span>
###xml 1348 1352 <span type="species:ncbi:10090">mice</span>
###xml 1588 1592 <span type="species:ncbi:10090">mice</span>
###xml 1631 1635 <span type="species:ncbi:10090">mice</span>
###xml 1841 1845 <span type="species:ncbi:10090">mice</span>
###xml 2175 2180 <span type="species:ncbi:10090">mouse</span>
###xml 2192 2196 <span type="species:ncbi:10090">mice</span>
###xml 2238 2243 <span type="species:ncbi:10090">mouse</span>
###xml 2338 2342 <span type="species:ncbi:10090">mice</span>
Treatment of virus-infected mice with anti-IL-17 antibody elevates antiviral cytotoxic T cell function. (A) Flow cytometry of CNS-infiltrating cells from SJL mice treated with isotype or anti-IL-17 antibody at 8 d after infection (percentages are shown). The bar graph represents numbers of CNS-infiltrating CD45hiCD11b+ macrophages and resident CD45intCD11b+ microglia. ***, P < 0.001 for anti-IL-17 versus isotype antibody-treated groups. (B and C) Intracellular expression of Bcl-xl and Bcl-2 in CNS macrophages and microglia (B) and CNS-infiltrating CD4+ and CD8+ T cells (C) isolated from SJL mice treated with isotype or anti-IL-17 antibody. Shaded and open histograms represent cells stained with isotype control and anti-Bcl antibodies, respectively. The number in each histogram shows the relative median fluorescence intensity difference between cells stained with anti-Bcl antibody and isotope control antibody. (D) Intracellular cytokine production by CNS-infiltrating cells from isotype or anti-IL-17 antibody-treated SJL mice was determined. The number in each plot indicates the frequency of IFN-gamma-producing CD8+ T cells. The bar graph represents numbers of IFN-gamma-producing viral epitope-specific CD8+ T cells. *, P < 0.05, anti-IL-17 versus isotope antibody-treated groups. Data in A-D represent pooled CNS cells from three mice per group and are representative samples of three separate experiments (means +/- SD are shown in A and D). (E) Enhanced lysis of dominant epitope VP3159-166- and subdominant epitope VP3173-181-loaded target cells in TMEV-infected SJL mice treated with anti-IL-17 antibody. SJL mice were treated with either isotype (n = 3) or anti-IL-17 (n = 3) antibody at days 0 and 7 relative to TMEV infection. At 8 d after infection, in vivo lysis activity was evaluated in virus- and mock-infected mice (n = 3) that received the target cell injection. The numbers in each histogram show the percentages of CFSE-labeled virus epitope-loaded (lower fluorescence intensity) and OVA323-339-loaded (higher fluorescence intensity) target cells, respectively. The arrows represent the virus epitope-loaded target cells. One representative mouse from three mice per group is shown. The pattern of every mouse in each group was very consistent. These experiments were repeated once with three additional mice.
###end p 27
###begin title 28
DISCUSSION
###end title 28
###begin p 29
###xml 96 97 96 97 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
We have presented evidence in this paper that virus-infected DCs polarize the development of CD4+ T cells toward the Th17 type. During acute viral infection, Th17 cytokine IL-17 promotes virus-induced inflammatory mediators in permissive cells to form a pathogenic inflammatory milieu, as well as to protect cells from both virus- and effector T cell-induced apoptosis, resulting in chronic viral persistence and demyelinating disease. By interfering with cytolytic T cell function, IL-17 blocks vigorous and efficient antiviral immunity, thereby permitting sustained viral infection. This IL-17-mediated feedback loop during viral infection favors viral escape from powerful antiviral effector T cells. These properties of Th17 cells represent a previously unknown mechanism of viral persistence leading to the pathogenesis of virus-induced chronic diseases.
###end p 29
###begin p 30
###xml 85 91 85 91 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1</xref>
###xml 190 191 190 191 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 441 447 441 447 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Fig. 2</xref>
###xml 587 602 587 602 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1, A vs. E</xref>
###xml 761 767 761 767 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3</xref>
###xml 945 947 945 947 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib39">39</xref>
###xml 1075 1077 1075 1077 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib30">30</xref>
###xml 1079 1081 1079 1081 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib40">40</xref>
###xml 1212 1218 1212 1218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1</xref>
###xml 1256 1262 1256 1262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3</xref>
###xml 1529 1531 1529 1531 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib30">30</xref>
###xml 1533 1535 1533 1535 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib40">40</xref>
###xml 1536 1538 1536 1538 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib42">42</xref>
###xml 1654 1656 1651 1653 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib39">39</xref>
###xml 1811 1812 1802 1803 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib6">6</xref>
###xml 1813 1814 1804 1805 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib8">8</xref>
###xml 419 423 <span type="species:ncbi:10090">mice</span>
###xml 435 439 <span type="species:ncbi:10090">mice</span>
###xml 507 511 <span type="species:ncbi:10090">mice</span>
###xml 755 759 <span type="species:ncbi:10090">mice</span>
###xml 864 868 <span type="species:ncbi:10090">mice</span>
###xml 939 943 <span type="species:ncbi:10090">mice</span>
###xml 1069 1073 <span type="species:ncbi:10090">mice</span>
###xml 1250 1254 <span type="species:ncbi:10090">mice</span>
###xml 1629 1633 <span type="species:ncbi:10090">mice</span>
###xml 1648 1652 <span type="species:ncbi:10090">mice</span>
Our data show that TMEV-infected DCs promote the development of Th17 cells in vitro (Fig. 1). These results strongly suggest that virus infection harnesses the ability of DCs to polarize CD4+ T cells toward Th17 cells. In particular, IL-6 produced by DCs after viral infection appears to steer this skewed Th17 cell development. It is interesting to note that higher levels of Th17 cells are found in TMEV-infected SJL mice than in B6 mice (Fig. 2). This difference between resistant B6 and susceptible SJL mice may reflect the differential level of Th17 cell generation induced by DCs (Fig. 1, A vs. E; and Fig. S2). LPS treatment likely enhances virus-infected DCs to induce Th17 development to the pathogenic threshold of Th17 response in resistant B6 mice (Fig. 3), as shown in vitro (Fig. S2). This difference in Th17 cell levels in the CNS of virus-infected mice correlates with IL-6 levels produced both in the CNS of TMEV-infected mice (39) and by in vitro-infected antigen-presenting cells, including DCs and microglia from susceptible SJL versus resistant B6 mice (30, 40). An elevated level of IL-6 appears to be necessary for this skewing of Th17 cell differentiation by virus-infected DCs in vitro (Fig. 1), as well as in virus-infected mice (Fig. 3). It is conceivable that the cellular sources of IL-6 during virus infection may also include many different CNS-resident cells such as microglia and astrocytes, which serve as major potential viral reservoirs, and infiltrating cells, including DCs and macrophages (30, 40-42). Moreover, preferential expression of TGF-beta was found in the CNS of TMEV-infected SJL mice but not in B6 mice (39), suggesting that TGF-beta may also participate in the development of Th17 cells in the CNS, because the differentiation of Th17 cells requires TGF-beta (6-8). Thus, innate inflammatory responses to TMEV infection in DCs and other antigen-presenting cells would most likely affect the development of Th17 cells, leading to a critical modulation of adaptive immune responses involved in virus-host interactions.
###end p 30
###begin p 31
###xml 223 225 223 225 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib28">28</xref>
###xml 227 229 227 229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib29">29</xref>
###xml 362 364 362 364 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib43">43</xref>
###xml 675 681 675 681 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Fig. 5</xref>
###xml 1050 1052 1050 1052 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib44">44</xref>
###xml 28 32 <span type="species:ncbi:10090">mice</span>
###xml 159 163 <span type="species:ncbi:10090">mice</span>
###xml 925 941 <span type="species:ncbi:169066">human rhinovirus</span>
###xml 1012 1017 <span type="species:ncbi:9606">human</span>
###xml 1032 1037 <span type="species:ncbi:10090">mouse</span>
In contrast to resistant B6 mice that display rapid viral clearance and the absence of demyelinating disease development after TMEV infection, susceptible SJL mice exhibit chronic viral persistence and disease progression (28, 29). Active viral replication is a critical determinant for persistent infection and the development of chronic demyelinating disease (43). In addition, virally induced inflammatory mediators may also contribute to this harmful process. Although IL-17 does not directly enhance TMEV infection/replication in permissive cells, this cytokine significantly increases the production of virus-induced inflammatory mediators such as IL-6, KC, and MCP-1 (Fig. 5). This suggests that IL-17-mediated signals amplify virus-induced innate responses involved in CNS inflammation, which leads to chronic demyelination. Consistent with our findings, a recent report indicated that IL-17 synergistically enhances human rhinovirus-16-induced epithelial production of the inflammatory mediator IL-8, a human homologue for mouse KC protein (44).
###end p 31
###begin p 32
###xml 38 39 38 39 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 152 154 152 154 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib28">28</xref>
###xml 156 158 156 158 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib29">29</xref>
###xml 187 188 187 188 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 429 430 429 430 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 460 461 460 461 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 712 713 712 713 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 757 759 757 759 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib45">45</xref>
###xml 1075 1076 1071 1072 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib2">2</xref>
###xml 1078 1079 1074 1075 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib5">5</xref>
###xml 1080 1081 1076 1077 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib9">9</xref>
###xml 1166 1168 1162 1164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib17">17</xref>
###xml 1367 1368 1363 1364 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1497 1499 1493 1495 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib25">25</xref>
###xml 1663 1669 1659 1665 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4</xref>
###xml 1784 1785 1780 1781 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib4">4</xref>
###xml 1787 1789 1783 1785 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib11">11</xref>
###xml 2321 2328 2317 2324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Figs. 3</xref>
###xml 2333 2334 2329 2330 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">4</xref>
###xml 2934 2936 2930 2932 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib46">46</xref>
###xml 2937 2939 2933 2935 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib49">49</xref>
###xml 259 263 <span type="species:ncbi:10090">mice</span>
###xml 568 572 <span type="species:ncbi:10090">mice</span>
###xml 1151 1154 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1255 1259 <span type="species:ncbi:10090">mice</span>
###xml 1384 1388 <span type="species:ncbi:10090">mice</span>
###xml 1758 1763 <span type="species:ncbi:9606">human</span>
###xml 2092 2097 <span type="species:ncbi:10090">mouse</span>
###xml 2145 2149 <span type="species:ncbi:10090">mice</span>
###xml 2204 2208 <span type="species:ncbi:10090">mice</span>
###xml 2414 2418 <span type="species:ncbi:10090">mice</span>
###xml 2856 2861 <span type="species:ncbi:9606">human</span>
Previously, the pathogenic role of CD4+ T cells had been proposed based on delayed disease development after treatment with anti-MHC class II antibody (28, 29). The protective role of CD4+ T cells has also been noted, as virus-infected CD4 or MHC class II KO mice succumb to TMEV-induced demyelinating diseases. However, these studies are difficult to interpret partly because of the lack of protective Th1 as well as reduced CD8+ T cells in the absence of CD4+ T cell help. It is interesting to note that immunization with CD4 epitope before viral infection protects mice from disease development, whereas such immunization after viral infection exacerbates disease progression, suggesting that expansion of CD4+ T cells after infection may be pathogenic (45). Although the protective roles of Th1 and its hallmark cytokine, IFN-gamma, have been previously documented, the roles of Th17 and IL-17 in viral infection-induced inflammatory disease remain undefined. This cell linage plays a critical role in the protection against extracellular bacterial or fungal infections (2, 5-9). In contrast, virus-specific Th17 cells are detectable during early HIV infection (17), suggesting that Th17 cells may be associated with viral replication. Interestingly, mice lacking both of the transcription factors T-bet and eomesodermin develop high levels of IL-17-producing CD8+ T cells; these mice develop a progressive inflammatory and wasting syndrome after lymphocytic choriomeningitis viral infection (25). Our results clearly demonstrate that Th17 cells and their cytokine IL-17 play a critical role in the pathogenesis of TMEV-induced chronic demyelinating disease (Fig. 4), similar to that shown with experimental autoimmune encephalomyelitis and perhaps also human multiple sclerosis (4, 11). Therefore, it is most likely that the pathogenic function of infection-induced Th17 cells observed with the TMEV model system is also applicable to other persistent viral infections, although this has yet to be determined. Furthermore, our data indicate that the pathogenic role of Th17 cells is not mouse strain specific. Both genetically resistant B6 mice in conjunction with LPS treatment and susceptible SJL mice induce elevated Th17 responses and chronic viral infection leading to the development of demyelinating disease (Figs. 3 and 4). In particular, demyelinating disease development in genetically resistant B6 mice in conjunction with LPS treatment suggests that a cytokine milieu induced by opportunistic infections of bacterial agents promotes Th17 responses during viral infection, leading to viral persistence and chronic infection-associated diseases. Such an enhanced development of pathogenic Th17 responses may result in clinical episodes in which the timing of infection strongly coincides with the exacerbation of severe clinical symptoms in human multiple sclerosis, as well as in acute disseminated encephalomyelitis (46-49).
###end p 32
###begin p 33
###xml 82 83 82 83 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 102 109 102 109 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig6">Figs. 6</xref>
###xml 114 115 114 115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig7">7</xref>
###xml 154 155 154 155 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 422 424 422 424 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib50">50</xref>
###xml 426 428 426 428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib51">51</xref>
###xml 494 495 494 495 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 576 577 576 577 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 633 635 633 635 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib52">52</xref>
###xml 766 768 766 768 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib53">53</xref>
###xml 769 771 769 771 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib55">55</xref>
###xml 847 848 847 848 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 918 920 918 920 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib37">37</xref>
###xml 922 924 922 924 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib38">38</xref>
###xml 926 928 926 928 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib56">56</xref>
###xml 1025 1026 1025 1026 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1034 1035 1034 1035 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1156 1162 1156 1162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig6">Fig. 6</xref>
###xml 1261 1263 1261 1263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib57">57</xref>
###xml 1649 1650 1645 1646 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1673 1675 1669 1671 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib58">58</xref>
###xml 1676 1678 1672 1674 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib61">61</xref>
###xml 1723 1729 1719 1725 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Tmevp3</italic>
###xml 1800 1802 1796 1798 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib62">62</xref>
###xml 253 257 <span type="species:ncbi:10090">mice</span>
One intriguing finding in this study is that IL-17 impairs antiviral cytotoxic CD8+ T cell responses (Figs. 6 and 7). This regulatory role of IL-17 on CD8+ T cell function had not previously been identified. In our system, TMEV infection in susceptible mice promotes the generation of Th17 cells that compromise antiviral cytotoxic T cell function via IL-17 production. Previous findings that IL-17 promotes tumor growth (50, 51) may also reflect the inhibitory effect of IL-17 on cytotoxic CD8+ T function against target tumor cells. It is well established that cytotoxic CD8+ T cells confer protective immunity to viral infection (52) by secreting antiviral cytokines or inducing the cytolysis of infected cells via the granule exocytosis and/or Fas-FasL pathway (53-55). In addition, similar cytolysis of virus-infected cells is observed by CD4+ T cells in an MHC class II-restricted manner during virus infection (37, 38, 56). Our results indicate that IL-17 interferes with the Fas-FasL pathway of cytotoxic effector CD4+ and CD8+ T cells by protecting target cells against apoptosis, possibly through the up-regulation of their prosurvival proteins (Fig. 6). Because an IL-17 receptor-like gene has recently been identified as a novel antiapoptotic gene (57), it is conceivable that the IL-17 receptor may have such an antiapoptotic property. Furthermore, Th17 cytokines other than IL-17 may be able to modulate protective antiviral T cell responses. For example, IL-21, an essential cytokine for the induction and maintenance of Th17 cells, has the potential to suppress the production of IFN-gamma by T lymphocytes and to drive cytotoxic CD8+ T cells to apoptosis (58-61). In addition, a TMEV susceptibility locus, Tmevp3, coincides with the IL-22 gene, which encodes IL-22, a Th17 cytokine (62), suggesting a potential role of this T cell population in the development of demyelinating disease. More studies with these cytokines would be helpful in clarifying the role of Th17 cells in the establishment of viral persistence and the consequent pathogenesis of virus-induced chronic inflammatory diseases.
###end p 33
###begin p 34
###xml 91 95 <span type="species:ncbi:10090">mice</span>
In summary, viral infection in antigen-presenting cells in vitro as well as in susceptible mice in vivo induces elevated IL-6 production that subsequently promotes the development of pathogenic Th17 cells. Th17 cells and their cytokine IL-17 are potent promoters of viral persistence and the development of virally induced chronic inflammatory demyelinating disease. IL-17 inhibits virus-induced cell apoptosis; this protection of virus-infected cells serves as a powerful means for viral evasion of the immune system. The inhibition of apoptosis prolongs the life of infected cells on the one hand, and desensitizes killing by cytotoxic T cells on the other, resulting in enhanced viral replication and persistence. The virus-host interaction via Th17 cells and/or their cytokine IL-17 results in the establishment of persistent viral infection and harmful immune responses, leading to the pathogenesis of TMEV-induced demyelinating disease. Conversely, interference with this interaction by neutralizing IL-17 activity reduces lymphocyte infiltration to the CNS and inhibits disease development. This particular interaction may also potentially operate in other chronic diseases associated with a variety of viral infections and could be a target for therapeutic intervention.
###end p 34
###begin title 35
MATERIALS AND METHODS
###end title 35
###begin title 36

###end title 36
###begin title 37
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice.
###end title 37
###begin p 38
###xml 97 100 97 100 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 374 379 374 379 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">74-86</sub>
###xml 491 493 491 493 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib63">63</xref>
###xml 36 40 <span type="species:ncbi:10090">mice</span>
###xml 102 106 <span type="species:ncbi:10090">mice</span>
###xml 180 184 <span type="species:ncbi:10090">mice</span>
###xml 312 327 <span type="species:ncbi:10090">transgenic mice</span>
###xml 485 489 <span type="species:ncbi:10090">mice</span>
###xml 574 578 <span type="species:ncbi:10090">mice</span>
###xml 603 607 <span type="species:ncbi:10090">mice</span>
Female SJL/J (SJL) and C57BL/6 (B6) mice were purchased from Harlan Sprague Dawley. IL-6 KO (IL-6-/-) mice on a B6 background were obtained from the Jackson Laboratory. 6-8-wk-old mice were maintained and used according to the protocols approved by the Northwestern University Animal Care and Use Committee. TCR transgenic mice that recognize TMEV capsid protein peptide VP274-86 were generated with the genomic DNA of a T cell clone derived from the spinal cords of TMEV-infected SJL mice (63) by the Transgenic Core Facility at Northwestern University. Transgenic founder mice were backcrossed to SJL mice at least 14 generations.
###end p 38
###begin title 39
TMEV-induced demyelinating diseases.
###end title 39
###begin p 40
###xml 53 54 49 50 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 168 170 164 166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib30">30</xref>
###xml 284 301 272 289 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"> Escherichia coli</italic>
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
###xml 206 210 <span type="species:ncbi:10090">mice</span>
###xml 278 283 <span type="species:ncbi:10090">mouse</span>
###xml 285 301 <span type="species:ncbi:562">Escherichia coli</span>
###xml 408 412 <span type="species:ncbi:10090">mice</span>
###xml 466 471 <span type="species:ncbi:10090">mouse</span>
Mice were intracerebrally infected with 30 microl (106 PFU) of the BeAn strain of TMEV, and clinical symptoms of disease were assessed weekly, as previously described (30). For LPS treatment, B6 or IL-6 KO mice were intraperitoneally injected with LPS (20 microg/100 microl per mouse; Escherichia coli 0111:B4; Sigma-Aldrich) at days 0 and 5 relative to viral infection. For neutralization of IL-17 in vivo, mice were intraperitoneally injected with 100 microg anti-mouse IL-17A antibody (clone eBioMM17F3; eBioscience) in 200 microl at days 0, 7, and 14 relative to viral infection.
###end p 40
###begin title 41
BMDCs, primary astrocyte cultures, and viral infection/replication assay.
###end title 41
###begin p 42
###xml 81 83 81 83 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib30">30</xref>
###xml 85 87 85 87 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib64">64</xref>
###xml 201 203 201 203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib42">42</xref>
###xml 309 311 309 311 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib30">30</xref>
###xml 473 475 473 475 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib65">65</xref>
###xml 746 748 746 748 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib30">30</xref>
###xml 407 411 <span type="species:ncbi:9925">goat</span>
###xml 449 454 <span type="species:ncbi:10090">mouse</span>
###xml 505 509 <span type="species:ncbi:9925">goat</span>
###xml 515 520 <span type="species:ncbi:10090">mouse</span>
BMDCs were generated in the presence of GM-CSF for 5 d, as previously described (30, 64). Primary astrocytes were generated from 1-3-d-old B6 neonates by differential shaking, as previously described (42). Virus infection/replication assays were performed 24 h after viral infection, as previously described (30). Cells were subsequently fixed, permeabilized (perm/fix solution; BD), blocked with 1% normal goat serum (Invitrogen), and stained with mouse anti-TMEV 8C mAb (65) followed by FITC-conjugated goat anti-mouse secondary antibody (Invitrogen). BMDCs were further stained with anti-CD11c-allophycocyanin (APC; BD). Levels of infectious virus in culture supernatants were determined with a standard plaque assay, as previously described (30). The cytokines in culture supernatants were analyzed using ELISA kits for IL-6, IL-12p40, IL-12p70, and MCP-1 (OptEIA; BD); for IL-23 (eBioscience); and for KC (R&D Systems). For the cell death assay, adult B6 BM cells from a 2-d culture with GM-CSF, BMDCs from a 5-d culture, and neonatal astrocytes were infected for 24 h with TMEV (multiplicity of infection [MOI] of 10) in the presence or absence of 100 ng/ml IL-17 (PeproTech), and were then stained with APC-conjugated Annexin V (Invitrogen).
###end p 42
###begin title 43
Isolation of CNS-infiltrated leukocytes and assessment of virus antigen-specific responses.
###end title 43
###begin p 44
###xml 92 94 92 94 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib30">30</xref>
###xml 320 325 312 317 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">25-38</sub>
###xml 333 340 325 332 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">206-220</sub>
###xml 382 389 370 377 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">121-130</sub>
###xml 394 401 382 389 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">110-120</sub>
###xml 410 417 398 405 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165-173</sub>
###xml 445 447 433 435 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib66">66</xref>
###xml 540 542 528 530 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib67">67</xref>
###xml 61 65 <span type="species:ncbi:10090">mice</span>
###xml 226 230 <span type="species:ncbi:10090">mice</span>
CNS-infiltrating leukocytes were isolated from TMEV-infected mice, as previously described (30). Isolated CNS-infiltrating leukocytes were restimulated with different doses of UV-TMEV for 48 h. Splenocytes from virus-infected mice were cultured in the presence of 1 microg/ml UV-TMEV, 2 microM of mixed CD4 epitopes (VP425-38 and VP2206-220), and 2 microM of mixed CD8 epitopes (VP2121-130, VP3110-120, and VP2165-173), as previously described (66). All peptides were synthesized by GeneMed Synthesis Inc. and used as previously described (67). IFN-gamma and IL-17 levels in culture supernatants were assessed using ELISA kits (from BD [OptEIA] and R&D Systems, respectively).
###end p 44
###begin title 45
Measurement of viral persistence in the CNS.
###end title 45
###begin p 46
###xml 211 213 211 213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib30">30</xref>
###xml 57 61 <span type="species:ncbi:10090">mice</span>
Brains and spinal cords were isolated from TMEV-infected mice after cardiac perfusion with Hank's buffered salt solution. A standard plaque assay was performed using tissue homogenates, as previously described (30).
###end p 46
###begin title 47
Intracellular staining and flow cytometry.
###end title 47
###begin p 48
###xml 70 71 70 71 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 234 241 234 241 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">323-339</sub>
###xml 634 636 626 628 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib30">30</xref>
###xml 915 916 907 908 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1072 1079 1060 1067 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">159-166</sub>
###xml 1106 1113 1094 1101 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">173-181</sub>
###xml 105 109 <span type="species:ncbi:10090">mice</span>
###xml 302 307 <span type="species:ncbi:10090">mouse</span>
###xml 764 768 <span type="species:ncbi:10090">mice</span>
###xml 1485 1490 <span type="species:ncbi:10090">mouse</span>
###xml 1544 1549 <span type="species:ncbi:10090">mouse</span>
###xml 1734 1738 <span type="species:ncbi:10090">mice</span>
###xml 1852 1857 <span type="species:ncbi:10090">mouse</span>
###xml 1876 1881 <span type="species:ncbi:10090">mouse</span>
###xml 1945 1950 <span type="species:ncbi:10090">mouse</span>
###xml 1967 1972 <span type="species:ncbi:10090">mouse</span>
###xml 2035 2040 <span type="species:ncbi:10090">mouse</span>
###xml 2061 2066 <span type="species:ncbi:10090">mouse</span>
For assessment of cytokine production by OT-II transgenic T cells, CD4+ T cells were isolated from OT-II mice by positive immunomagnetic cell sorting (Miltenyi Biotec), primed with mock or TMEV-infected B6 BMDCs in the presence of OVA323-339 for 4 d with or without IL-6 (both from PeproTech), or anti-mouse IL-6 antibody (Invitrogen). These cultures were restimulated with 50 ng/ml PMA and 1 microg/ml ionomycin (Sigma-Aldrich) for 6 h and were stained with anti-IFN-gamma-APC, anti-IL-17-PE, and anti-CD4-FITC (all from BD). In some experiments, BMDCs were left unfixed or fixed with 0.1% paraformaldehyde, as previously described (30). To determine the level of IL-17 production by the whole CNS cells, CNS-infiltrating leukocytes from TMEV-infected SJL and B6 mice at 8 d after infection were cultured with PMA plus ionomycin for 6 h and analyzed by flow cytometry. Levels of virus-specific CNS-infiltrating CD8+ T cells were assessed by flow cytometry after intracellular staining of IFN-gamma after stimulating CNS mononuclear cells for 6 h with dominant epitope VP3159-166 or subdominant epitope VP3173-181. All antibodies used in flow cytometry for cellular markers were purchased from BD. To analyze the expression of prosurvival proteins, splenic B cells were isolated by using anti-CD19 MicroBeads (Miltenyi Biotec). B cells stimulated with 10 microg/ml LPS, BM cells, and BMDCs were treated for 24 h with or without 100 ng/ml IL-17. These cells were then stained with anti-mouse Bcl-xl-FITC (Santa Cruz Biotechnology, Inc.) or anti-mouse Bcl-2-FITC (eBioscience) and analyzed using flow cytometry. To determine expression levels of prosurvival proteins in vivo, CNS-infiltrating cells were isolated from TMEV-infected SJL mice treated with anti-IL-17 antibody at days 0 and 7 relative to viral infection. These cells were stained with anti-mouse CD45-APC and anti-mouse CD11b-PE (both from BD) for antigen-presenting cells, and anti-mouse CD4-APC or anti-mouse CD8-APC for T cells. All cells were further stained with anti-mouse Bcl-xl-FITC or anti-mouse Bcl-2-FITC and analyzed using flow cytometry.
###end p 48
###begin title 49
Cytokine production assays.
###end title 49
###begin p 50
###xml 70 71 70 71 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 84 85 84 85 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 89 90 89 90 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 94 97 94 97 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">low</sup>
###xml 192 197 188 193 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">74-86</sub>
To assess cytokine production by VP2-TCR transgenic T cells, naive CD4+ T cells (CD4+CD25-CD44low) sorted using a MoFlo (Dako) were co-cultured for 4 d with BMDCs pulsed with PBS, 2 microM VP274-86, or 1 microg/ml UV-TMEV, or were infected with TMEV overnight. IL-17, IL-22, and TNF-alpha levels in culture supernatants were assessed using ELISA kits (from R&D System, Antigenix America Inc., and BD [OptEIA], respectively).
###end p 50
###begin title 51
Quantitative analysis of mRNAs.
###end title 51
###begin p 52
###xml 57 58 57 58 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 61 62 61 62 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 67 68 67 68 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 71 72 71 72 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 81 82 81 82 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 85 86 85 86 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 378 380 370 372 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib29">29</xref>
###xml 382 384 374 376 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib68">68</xref>
###xml 130 134 <span type="species:ncbi:10090">mice</span>
Total RNA was extracted with TRIzol (Invitrogen) from CD4+CD8-, CD4-CD8+, and CD4-CD8- mononuclear cells in the CNS of SJL and B6 mice by sorting on a MoFlo cytometer at 8 d after TMEV infection. Reverse transcription was performed using 1-3 microg of total RNA. The sense and antisense primer sequences for IL-17, RORgammat, and GADPH were synthesized as previously described (29, 68). Specific RNA messages were amplified in SYBR green I mastermix (Bio-Rad Laboratories) by real-time PCR using an iCycler (Bio-Rad Laboratories). Expression levels of IL-17 and RORgammat mRNAs were determined by comparison to GADPH expression. All real-time RCR was performed in triplicate.
###end p 52
###begin title 53
Cytotoxic activity assay.
###end title 53
###begin p 54
###xml 3 10 3 10 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">121-130</sub>
###xml 70 72 70 72 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">51</sup>
###xml 146 147 146 147 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 255 257 255 257 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib67">67</xref>
###xml 366 373 366 373 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">121-130</sub>
###xml 401 408 401 408 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">323-339</sub>
###xml 1259 1260 1251 1252 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1351 1353 1343 1345 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib69">69</xref>
###xml 1618 1619 1602 1603 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1932 1939 1912 1919 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">159-166</sub>
###xml 1946 1953 1926 1933 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">173-181</sub>
###xml 1981 1988 1961 1968 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">323-339</sub>
###xml 2114 2115 2094 2095 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">7</sup>
###xml 199 203 <span type="species:ncbi:10090">mice</span>
###xml 578 582 <span type="species:ncbi:10090">mice</span>
###xml 924 929 <span type="species:ncbi:9606">human</span>
###xml 1397 1401 <span type="species:ncbi:10090">mice</span>
###xml 1639 1643 <span type="species:ncbi:10090">mice</span>
###xml 2132 2137 <span type="species:ncbi:10090">mouse</span>
###xml 2197 2201 <span type="species:ncbi:10090">mice</span>
VP2121-130-loaded EL-4 cells were used as target cells for a standard 51Cr-release assay to assess the short-term cytoxicity by virus-specific CD8+ T cells, which were isolated from the spleen of B6 mice 8 d after TMEV infection, as previously described (67). For the long-term cytoxicity assay, aliquots of naive B6 splenocytes were pulsed with cognate peptide (VP2121-130) or irrelevant peptide (OVA323-339), and further labeled with low or high concentrations of CSFE, respectively. These labeled target cells were then co-cultured for 60 h with effector splenocytes from B6 mice at 8 d after TMEV infection at different effector/target (E/T) ratios in the presence or absence of 100 ng/ml IL-17F or IL-17 (PeproTech). In parallel experiments, labeled target and effector cells were pretreated separately with IL-17 for 24 h, and were then washed and co-cultured for 60 h. In some experiments, 1 microg/ml of recombinant human Fas:Fc and 1 microg/ml enhancer for receptors (both from Enzo Biochem, Inc.) were added to co-cultures to inhibit the Fas-FasL pathway. For apoptosis assays of effector and target cells, cells from the co-cultures at an E/T ratio of 10:1 for 24 h were stained with anti-CD8-PE (BD) and APC-conjugated Annexin V. The activated CD4+ T cell-mediated cognate cytolysis of target B cells was analyzed as previously described (69). In brief, B cells purified from naive B6 mice by positive immunomagnetic cell sorting (Miltenyi Biotec) were stimulated with 10 microg/ml LPS for 20 h and pulsed with 100 microg/ml OVA for the final 2 h, and then cultured for 24 h at an E/T ratio of 5:1 with CD4+ T cells from OT-II mice preactivated for 4 d with anti-CD3 plus anti-CD28 mAbs (both BD) in the presence of 0.5 microg/ml LPS. Cells were stained with anti-CD45R/B220-PE (BD) and APC-conjugated Annexin V. For in vivo cytolysis assays, aliquots of naive SJL splenocytes were pulsed with viral epitope peptide (VP3159-166 or VP3173-181) or irrelevant peptide (OVA323-339), and respectively labeled with low or high concentrations of CSFE. The mixture of these two populations in equal numbers (107 total cells per mouse) was intravenously injected into mock or TMEV-infected SJL mice. After 15-18 h, splenocytes were isolated from recipients, and the relative numbers of each CFSE-stained population were assessed by flow cytometry.
###end p 54
###begin title 55
Statistical analysis.
###end title 55
###begin p 56
###xml 88 89 86 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 308 309 306 307 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
The results were expressed as the mean +/- SD, where applicable. The unpaired Student's t test was used to compare the two independent groups. Differences in mean incidence and severity score between the two experimental groups were compared between 21 and 84 d after infection by using the paired Student's t test. P < 0.05 was considered to be significant.
###end p 56
###begin title 57
Online supplemental material.
###end title 57
###begin p 58
###xml 258 259 258 259 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 295 299 <span type="species:ncbi:10090">mice</span>
###xml 409 413 <span type="species:ncbi:10090">mice</span>
Fig. S1 shows the enhanced Th17 development during persistent viral infection. Fig. S2 demonstrates the elevated differentiation of Th17 cells induced by virus-infected DCs in the presence of LPS. Fig. S3 shows the cytokine production by CNS-infiltrating CD8+ T cells after TMEV infection in B6 mice treated with anti-IL-17 antibodies. Fig. S4 compares the histopathology and viral persistence levels between mice treated with anti-IL-17 and control antibodies. Fig. S5 presents the expression of IL-17R on BM cells and the range of IL-17-induced protection against apoptosis triggered by various treatments. Online supplemental material is available at .
###end p 58
###begin title 59
Supplementary Material
###end title 59
###begin title 60
[Supplemental Material Index]
###end title 60
###begin p 61
We thank Drs. W. Ouyang and K. Rundell for their helpful comments, P. Kim for proofreading, J. Marvin and P. Mehl for cell sorting, and the Kim laboratory members for their assistance in this work.
###end p 61
###begin p 62
This work was supported by grants from the National Institutes of Health (RO1 NS28752 and RO1 NS33008) and the National Multiple Sclerosis Society (RG 4001-A6).
###end p 62
###begin p 63
The authors have no conflicting financial interests.
###end p 63
###begin article-title 64
Functional diversity of helper T lymphocytes.
###end article-title 64
###begin article-title 65
Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages.
###end article-title 65
###begin article-title 66
Th17: an effector CD4 T cell lineage with regulatory T cell ties.
###end article-title 66
###begin article-title 67
A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage.
###end article-title 67
###begin article-title 68
A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17.
###end article-title 68
###begin article-title 69
TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells.
###end article-title 69
###begin article-title 70
Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells.
###end article-title 70
###begin article-title 71
Transforming growth factor-beta induces development of the T(H)17 lineage.
###end article-title 71
###begin article-title 72
Th17 cell differentiation: the long and winding road.
###end article-title 72
###begin article-title 73
The biological functions of T helper 17 cell effector cytokines in inflammation.
###end article-title 73
###begin article-title 74
T(H)-17 cells in the circle of immunity and autoimmunity.
###end article-title 74
###begin article-title 75
TH17 cells in development: an updated view of their molecular identity and genetic programming.
###end article-title 75
###begin article-title 76
Induction and effector functions of T(H)17 cells.
###end article-title 76
###begin article-title 77
###xml 98 126 <span type="species:ncbi:12721">human immunodeficiency virus</span>
Increased interleukin-17 production both in helper T cell subset Th17 and CD4-negative T cells in human immunodeficiency virus infection.
###end article-title 77
###begin article-title 78
###xml 15 20 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 92 97 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Suppression of HIV-1 plasma viral load below detection preserves IL-17 producing T cells in HIV-1 infection.
###end article-title 78
###begin article-title 79
###xml 35 38 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
New players in cytokine control of HIV infection.
###end article-title 79
###begin article-title 80
###xml 77 112 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Virus-specific interleukin-17-producing CD4+ T cells are detectable in early human immunodeficiency virus type 1 infection.
###end article-title 80
###begin article-title 81
IL-17 receptor signaling influences virus-induced corneal inflammation.
###end article-title 81
###begin article-title 82
###xml 0 27 <span type="species:ncbi:12814">Respiratory syncytial virus</span>
Respiratory syncytial virus infection in the absence of STAT 1 results in airway dysfunction, airway mucus, and augmented IL-17 levels.
###end article-title 82
###begin article-title 83
Roles of alpha beta and gamma delta T cell subsets in viral immunity.
###end article-title 83
###begin article-title 84
###xml 81 91 81 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Salmonella</italic>
###xml 0 29 <span type="species:ncbi:11723">Simian immunodeficiency virus</span>
Simian immunodeficiency virus-induced mucosal interleukin-17 deficiency promotes Salmonella dissemination from the gut.
###end article-title 84
###begin article-title 85
###xml 85 89 <span type="species:ncbi:10090">mice</span>
The type I IFN induction pathway constrains Th17-mediated autoimmune inflammation in mice.
###end article-title 85
###begin article-title 86
Engagement of the type I interferon receptor on dendritic cells inhibits T helper 17 cell development: role of intracellular osteopontin.
###end article-title 86
###begin article-title 87
Viruses and interferons.
###end article-title 87
###begin article-title 88
Anomalous type 17 response to viral infection by CD8+ T cells lacking T-bet and eomesodermin.
###end article-title 88
###begin article-title 89
Interleukin 27 negatively regulates the development of interleukin 17-producing T helper cells during chronic inflammation of the central nervous system.
###end article-title 89
###begin article-title 90
###xml 21 26 <span type="species:ncbi:9606">human</span>
Chronically inflamed human tissues are infiltrated by highly differentiated Th17 lymphocytes.
###end article-title 90
###begin article-title 91
###xml 10 16 <span type="species:ncbi:10090">murine</span>
###xml 83 88 <span type="species:ncbi:9606">human</span>
Theiler's murine encephalomyelitis virus (TMEV)-induced demyelination: a model for human multiple sclerosis.
###end article-title 91
###begin article-title 92
The genetics of the persistent infection and demyelinating disease caused by Theiler's virus.
###end article-title 92
###begin article-title 93
Role of dendritic cells in differential susceptibility to viral demyelinating disease.
###end article-title 93
###begin article-title 94
Host and virus determinants of picornavirus pathogenesis and tropism.
###end article-title 94
###begin article-title 95
###xml 67 71 <span type="species:ncbi:10090">mice</span>
Treatment with bacterial LPS renders genetically resistant C57BL/6 mice susceptible to Theiler's virus-induced demyelinating disease.
###end article-title 95
###begin article-title 96
IL-12- and IL-23-modulated T cells induce distinct types of EAE based on histology, CNS chemokine profile, and response to cytokine inhibition.
###end article-title 96
###begin article-title 97
Theiler's virus-induced intrinsic apoptosis in M1-D macrophages is Bax mediated and restricts virus infectivity: a mechanism for persistence of a cytolytic virus.
###end article-title 97
###begin article-title 98
Interleukin-17 family members and inflammation.
###end article-title 98
###begin article-title 99
Comparison of Fas(Apo-1/CD95)- and perforin-mediated cytotoxicity in primary T lymphocytes.
###end article-title 99
###begin article-title 100
Cutting edge: MHC class II-restricted killing in vivo during viral infection.
###end article-title 100
###begin article-title 101
Potential role of CD4+ T cell-mediated apoptosis of activated astrocytes in Theiler's virus-induced demyelination.
###end article-title 101
###begin article-title 102
###xml 87 93 <span type="species:ncbi:10090">murine</span>
###xml 164 168 <span type="species:ncbi:10090">mice</span>
Differential expression of TGF-beta, IL-2, and other cytokines in the CNS of Theiler's murine encephalomyelitis virus-infected susceptible and resistant strains of mice.
###end article-title 102
###begin article-title 103
###xml 129 133 <span type="species:ncbi:10090">mice</span>
Differential virus replication, cytokine production, and antigen-presenting function by microglia from susceptible and resistant mice infected with Theiler's virus.
###end article-title 103
###begin article-title 104
###xml 132 136 <span type="species:ncbi:10090">mice</span>
Replication of Theiler's virus requires NF-kappaB-activation: higher viral replication and spreading in astrocytes from susceptible mice.
###end article-title 104
###begin article-title 105
###xml 91 97 <span type="species:ncbi:10090">murine</span>
Induction of chemokine and cytokine genes in astrocytes following infection with Theiler's murine encephalomyelitis virus is mediated by the Toll-like receptor 3.
###end article-title 105
###begin article-title 106
Transition from acute to persistent Theiler's virus infection requires active viral replication that drives proinflammatory cytokine expression and chronic demyelinating disease.
###end article-title 106
###begin article-title 107
###xml 26 31 <span type="species:ncbi:9606">human</span>
###xml 63 79 <span type="species:ncbi:169066">human rhinovirus</span>
Interleukin-17A modulates human airway epithelial responses to human rhinovirus infection.
###end article-title 107
###begin article-title 108
###xml 74 80 <span type="species:ncbi:10090">murine</span>
Initial capsid-specific CD4(+) T cell responses protect against Theiler's murine encephalomyelitisvirus-induced demyelinating disease.
###end article-title 108
###begin article-title 109
Prospective study on the relationship between infections and multiple sclerosis exacerbations.
###end article-title 109
###begin article-title 110
The risk of relapses in multiple sclerosis during systemic infections.
###end article-title 110
###begin article-title 111
Pathogenesis, diagnosis, and treatment of acute disseminated encephalomyelitis.
###end article-title 111
###begin article-title 112
Acute disseminated encephalomyelitis: current understanding and controversies.
###end article-title 112
###begin article-title 113
Interleukin-17 promotes angiogenesis and tumor growth.
###end article-title 113
###begin article-title 114
###xml 65 70 <span type="species:ncbi:9606">human</span>
###xml 106 110 <span type="species:ncbi:10090">mice</span>
IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis.
###end article-title 114
###begin article-title 115
CD8 T cell responses to infectious pathogens.
###end article-title 115
###begin article-title 116
Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity.
###end article-title 116
###begin article-title 117
Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways.
###end article-title 117
###begin article-title 118
CD8+ T cell effector mechanisms in resistance to infection.
###end article-title 118
###begin article-title 119
###xml 10 15 <span type="species:ncbi:9606">human</span>
Cytotoxic human CD4(+) T cells.
###end article-title 119
###begin article-title 120
Interleukin-17 receptor-like gene is a novel antiapoptotic gene highly expressed in androgen-independent prostate cancer.
###end article-title 120
###begin article-title 121
Immunology: narcissistic helpers.
###end article-title 121
###begin article-title 122
Essential autocrine regulation by IL-21 in the generation of inflammatory T cells.
###end article-title 122
###begin article-title 123
IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells.
###end article-title 123
###begin article-title 124
IL-21 induces apoptosis of antigen-specific CD8+ T lymphocytes.
###end article-title 124
###begin article-title 125
Interleukin 22 is a candidate gene for Tmevp3, a locus controlling Theiler's virus-induced neurological diseases.
###end article-title 125
###begin article-title 126
###xml 70 74 <span type="species:ncbi:10090">mice</span>
Clonal expansion of infiltrating T cells in the spinal cords of SJL/J mice infected with Theiler's virus.
###end article-title 126
###begin article-title 127
Pertussis toxin enhances Th1 responses by stimulation of dendritic cells.
###end article-title 127
###begin article-title 128
###xml 58 64 <span type="species:ncbi:10090">murine</span>
###xml 203 208 <span type="species:ncbi:10090">mouse</span>
Detection of restricted predominant epitopes of Theiler's murine encephalomyelitis virus capsid proteins expressed in the lambda gt11 system: differential patterns of antibody reactivity among different mouse strains.
###end article-title 128
###begin article-title 129
###xml 150 165 <span type="species:ncbi:10090">transgenic mice</span>
Anti-capsid immunity level, not viral persistence level, correlates with the progression of Theiler's virus-induced demyelinating disease in viral P1-transgenic mice.
###end article-title 129
###begin article-title 130
###xml 86 90 <span type="species:ncbi:10090">mice</span>
The immunodominant CD8+ T cell epitope region of Theiler's virus in resistant C57BL/6 mice is critical for anti-viral immune responses, viral persistence, and binding to the host cells.
###end article-title 130
###begin article-title 131
The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells.
###end article-title 131
###begin article-title 132
Activated CD4+CD25+ T cells selectively kill B lymphocytes.
###end article-title 132
###begin p 133
###xml 140 146 <span type="species:ncbi:10090">murine</span>
Abbreviations used: Bcl, B cell lymphoma; BMDC, BM-derived DC; CNS, central nervous system; MOI, multiplicity of infection; TMEV, Theiler's murine encephalomyelitis virus; UV-TMEV, UV light-inactivated TMEV.
###end p 133

